Literature DB >> 11817009

Multilayer vs. monolayer amniotic membrane transplantation for deep corneal ulcer treatment.

I Dekaris1, N Gabrić, I Mravicić, Z Karaman, J Katusić, R Lazić, N Spoljarić.   

Abstract

The purpose of the study was to evaluate the efficacy of multilayer amniotic transplantation (AMT) for reconstruction of corneal stroma and epithelium. Corneal ulcer (28) was a consequence of a previous infectious or neurotrophic keratitis. In the first group (17) ulcer was covered with monolayer AM, while in the other group (11) there were two or more layers of AM situated in the ulcer and the whole cornea was covered with AM sheet. Monolayer AMT was successful in 64% while the multilayer AMT success rate was 72%. AM gradually dissolved within 3-6 postoperative weeks. AM transplantation facilitates rapid healing of corneal epithelium, reduces inflammation and stimulates epithelial cell regrowth. In eyes with deep corneal ulcer multilayer technique proved to be better then monolayer procedure.

Entities:  

Mesh:

Year:  2001        PMID: 11817009

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  3 in total

1.  Role of multilayered amniotic membrane transplantation for the treatment of resistant corneal ulcers in North India.

Authors:  Shalini Mohan; Ina Budhiraja; Amit Saxena; Perwez Khan; S K Sachan
Journal:  Int Ophthalmol       Date:  2013-07-27       Impact factor: 2.031

2.  Study of self-made freeze-dried bilayered fibrin-binding amniotic membrane in ocular trabeculectomy in rabbits.

Authors:  Wan Li; Wen-Jian Che; Ming-Chang Zhang
Journal:  Int J Ophthalmol       Date:  2011-12-18       Impact factor: 1.779

Review 3.  Plumping up a Cushion of Human Biowaste in Regenerative Medicine: Novel Insights into a State-of-the-Art Reserve Arsenal.

Authors:  Nima Najafi-Ghalehlou; Alireza Feizkhah; Mohammadreza Mobayen; Zahra Pourmohammadi-Bejarpasi; Shima Shekarchi; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar
Journal:  Stem Cell Rev Rep       Date:  2022-05-03       Impact factor: 6.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.